{"id":527,"date":"2023-04-18T14:07:46","date_gmt":"2023-04-18T14:07:46","guid":{"rendered":"http:\/\/changingfaceofamerica.com\/?p=527"},"modified":"2023-04-18T14:07:46","modified_gmt":"2023-04-18T14:07:46","slug":"further-inquiries-can-be-directed-to-the-related-author","status":"publish","type":"post","link":"https:\/\/changingfaceofamerica.com\/?p=527","title":{"rendered":"\ufeffFurther inquiries can be directed to the related author"},"content":{"rendered":"

\ufeffFurther inquiries can be directed to the related author.. including dermatologic- and pulmonary-related adverse events [4, 5, 6]. Instances of infusion reactions following vedolizumab administration are uncommon. Only 5% of individuals receiving vedolizumab encounter an infusion-related reaction, much rarer than with anti-TNF [7, 8]. Here, we describe an atypical demonstration of an infusion reaction toward vedolizumab happening following long term maintenance therapy. Case Statement We present a case of a 67-year-old male having a past medical history positive for left-sided ulcerative colitis (UC) diagnosed at the age of 64 years. His history is also notable of chronic ischemic heart disease after coronary artery bypass surgery at the age Sitravatinib<\/a> of 47 years and several percutaneous coronary interventions since. Since the last coronary treatment at the age of 63 years, his heart disease was stable, and no symptoms of angina were reported. One year following UC analysis, biologic therapy with vedolizumab was initiated. After standard induction, the patient received infusions every 8 weeks for maintenance treatment. Due to medical and endoscopic exacerbation of his left-sided colitis, which necessitated hospitalization and steroidal therapy, therapy intervals were shortened to every 4 weeks. One-hundred and thirteen weeks after initiation of vedolizumab therapy, the patient presented with acute chest pain that started immediately upon commencement of a vedolizumab infusion. He reported intense pain radiating to the jaw, with Gpc4<\/a> alleviation several moments after infusion cessation. On demonstration, vital indications were normal, and no indications of an allergic reaction were obvious. Medical workup including chest x-ray, electrocardiogram, and laboratory blood checks for cardiac enzymes were negative excluding some other major reason for chest pain. After discharge, trough vedolizumab levels and anti-vedolizumab antibodies were obtained. Vedolizumab levels measured were zero, and antibodies were detectable (195 Sitravatinib mg\/dL, demonstrated in Fig. ?Fig.1;1; Table ?Table11). Open in a separate window Fig. 1 Flowchart showing vedolizumab drug levels and antidrug antibodies 6 months before and 10 days after acute chest pain. Table 1 Anti-vedolizumab antibody levels before and after acute chest pain reaction thead th align=”remaining” rowspan=”1″ colspan=”1″ Timeframe \/th th align=”remaining” rowspan=”1″ colspan=”1″ Antidrug antibodies \/th \/thead Six months prior chest pain83 mg\/dLTen days post chest pain195 mg\/dL Open in a separate window One month later on, several moments after initiation of the next vedolizumab infusion, similar symptoms of chest pain recurred. The infusion was halted, and the patient was referred to the emergency division. The symptoms subsided within hours and once again, no irregular findings on workup were recognized. Cardiac enzymes and an electrocardiogram were intact. In addition, a subsequent echocardiography ruled out structural heart disease or cardiac wall abnormalities that may imply of ischemia. Conversation In this case statement, we present an infusion reaction to long-term vedolizumab therapy manifesting as acute chest pain. Acute chest pain is definitely a symptom generally divided to cardiac or noncardiac causes. The causes range from life-threatening to relatively benign conditions. In primary care, the most common causes of chest pain are chest wall pain, gastroesophageal reflux disease, and costochondritis. However, cardiac-related conditions such as acute myocardial infarction and unstable angina are the leading causes of death. Chest pain can be a drug-related adverse effect. A variety of Sitravatinib common restorative agents have been recorded as potential causes including analgesics, antidepressants, antihistamines, hormones, antibiotics, and beta-agonist inhalers [9]. Chest pain related to anti-TNF therapy has been reported, manifesting as pleural effusion and pericarditis in a patient with Crohn’s disease that developed drug-induced lupus [10]. In our case, possible etiologies for chest pain were investigated and reasonably excluded twice based on medical data and laboratory findings in the emergency department and the internal medicine ward. In addition, the rechallenge of vedolizumab offered a certain analysis of the culprit agent. The recurrent chest pain following a consecutive infusion as well as the antidrug antibody pattern thin down the manifestation to an uncommon case of an infusion reaction. Infusion reactions to vedolizumab are rare and are generally well tolerated by individuals. The landmark studies in UC and CD possess reported infusion-related reaction rates of 5% and 4% of individuals, respectively [7, 8]. The majority of infusion-related reactions.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffFurther inquiries can be directed to the related author.. including dermatologic- and pulmonary-related adverse events [4, 5, 6]. Instances of infusion reactions following vedolizumab administration are uncommon. Only 5% of individuals receiving vedolizumab encounter an infusion-related reaction, much rarer than with anti-TNF [7, 8]. Here, we describe an atypical demonstration of an infusion reaction toward […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-527","post","type-post","status-publish","format-standard","hentry","category-antibiotics"],"_links":{"self":[{"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=527"}],"version-history":[{"count":1,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/527\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/527\/revisions\/528"}],"wp:attachment":[{"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/changingfaceofamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}